56
Participants
Start Date
December 31, 2011
Primary Completion Date
October 31, 2013
Study Completion Date
October 31, 2013
Rosuvastatin
After baseline assessment, the starting dose of rosuvastatin 10 mg will be given to study patients. If tolerated and LDL-C is \> 100mg/dL after 2-4 weeks, the dose will be increased to 20 mg. Rosuvastatin treatment is scheduled to continue for 1 year without no further dose titration, and each patient will be followed at 2 months, 6 months and 1 year.
Asan Medical Center, Seoul
Lead Sponsor
Collaborators (1)
AstraZeneca
INDUSTRY
Asan Medical Center
OTHER